| Schedule of intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2022 |
|
|
Estimated |
|
|
|
|
|
|
|
|
|
|
|
Useful |
|
Gross |
|
|
|
|
|
|
|
|
Lives |
|
Carrying |
|
Accumulated |
|
Intangble |
($'s in thousands) |
|
(Years) |
|
Value |
|
Amortizaiton |
|
Assets, Net |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Ceracade® |
|
|
3 |
|
$ |
300 |
|
$ |
(300) |
|
$ |
— |
Luxamend® |
|
|
3 |
|
|
50 |
|
|
(50) |
|
|
— |
Targadox® |
|
|
3 |
|
|
1,250 |
|
|
(1,250) |
|
|
— |
Ximino® |
|
|
7 |
|
|
7,134 |
|
|
(2,718) |
|
|
4,416 |
Exelderm® |
|
|
3 |
|
|
1,600 |
|
|
(1,600) |
|
|
— |
Accutane® |
|
|
5 |
|
|
4,727 |
|
|
(1,024) |
|
|
3,703 |
Amzeeq® |
|
|
9 |
|
|
15,162 |
|
|
(422) |
|
|
14,740 |
Zilxi® |
|
|
9 |
|
|
3,760 |
|
|
(104) |
|
|
3,656 |
|
|
|
|
|
|
33,983 |
|
|
(7,468) |
|
|
26,515 |
Non-amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Anti-itch product (1) |
|
|
3 |
|
|
3,942 |
|
|
— |
|
|
3,942 |
Total intangible assets |
|
|
|
|
$ |
37,925 |
|
$ |
(7,468) |
|
$ |
30,457 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
|
Estimated |
|
|
|
|
|
|
|
|
|
|
|
Useful |
|
Gross |
|
|
|
|
|
|
|
Lives |
|
Carrying |
|
Accumulated |
|
Intangble |
($'s in thousands) |
|
(Years) |
|
Value |
|
Amortizaiton |
|
Assets, Net |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Ceracade® |
|
|
3 |
|
$ |
300 |
|
$ |
(300) |
|
$ |
— |
Luxamend® |
|
|
3 |
|
|
50 |
|
|
(50) |
|
|
— |
Targadox® |
|
|
3 |
|
|
1,250 |
|
|
(1,250) |
|
|
— |
Ximino® |
|
|
7 |
|
|
7,134 |
|
|
(2,463) |
|
|
4,671 |
Exelderm® |
|
|
3 |
|
|
1,600 |
|
|
(1,600) |
|
|
— |
Accutane® |
|
|
5 |
|
|
4,727 |
|
|
(788) |
|
|
3,939 |
|
|
|
|
|
|
15,061 |
|
|
(6,451) |
|
|
8,610 |
Non-amortizable intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Anti-itch product (1) |
|
|
3 |
|
|
3,942 |
|
|
— |
|
|
3,942 |
Total intangible assets |
|
|
|
|
$ |
19,003 |
|
$ |
(6,451) |
|
$ |
12,552 |
| (1) |
The Company is transferring manufacturing to an existing contract manufacturer and upon validation will launch such product and commence amortizing. |
|
| Schedule of future amortization of intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
($’s in thousands) |
|
Ximino® |
|
Accutane® |
|
Amzeeq® |
|
Zilxi® |
|
Amortization |
Remainder of 2022 |
|
$ |
764 |
|
$ |
710 |
|
$ |
1,263 |
|
$ |
313 |
|
$ |
3,050 |
December 31, 2023 |
|
|
1,019 |
|
|
945 |
|
|
1,685 |
|
|
418 |
|
|
4,067 |
December 31, 2024 |
|
|
1,019 |
|
|
946 |
|
|
1,685 |
|
|
418 |
|
|
4,068 |
December 31, 2025 |
|
|
1,019 |
|
|
945 |
|
|
1,685 |
|
|
418 |
|
|
4,067 |
December 31, 2026 |
|
|
595 |
|
|
157 |
|
|
1,685 |
|
|
418 |
|
|
2,855 |
Thereafter |
|
|
— |
|
|
— |
|
|
6,737 |
|
|
1,671 |
|
|
8,408 |
Subtotal |
|
$ |
4,416 |
|
$ |
3,703 |
|
$ |
14,740 |
|
$ |
3,656 |
|
$ |
26,515 |
Asset not yet placed in service |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
3,942 |
Total |
|
$ |
4,416 |
|
$ |
3,703 |
|
$ |
14,740 |
|
$ |
3,656 |
|
$ |
30,457 |
|